Televisits for patients with atopic dermatitis treated with dupilumab: experience from a tertiary care center in Northern Italy.

Abstract

Background: Atopic dermatitis (AD) is an inflammatory skin disease. The monoclonal antibody dupilumab can provide a rapid response with achievement of stable clinical disease. This study aimed to confirm the effectiveness of a televisit approach for patients with AD and treated with dupilumab.

Methods: Demographic data and characteristics at baseline including mean EASI, mean NRSp, mean DLQI, and mean NRSds were retrospectively assessed and subsequently collected at up to 48 weeks, last visit in attendance, and up to the fourth televisit. The mean reduction of the above scores, and achievement at each time point of EASI≤7, EASI 75, EASI 90, DLQI 0/1, and NRSp≤4 were considered as endpoints.

Results: Twelve patients underwent at least 1 televisit. The mean follow-up on dupilumab before switching to a televisit was 28.5 months. The mean EASI at the last face-to-face visit was 0.75 and remained stable at subsequent televisit visits. All patients achieved EASI≤7 as early as week 16 which was during the televisits. A similar trend was seen for EASI 75. Only 1 patient discontinued the televisits after 2 visits, preferring to return in person.

Conclusions: In our case series of remotely-followed patients, clinical and patient-reported outcomes remained stable.